W Ludo Van Der Pol

List of Publications by Year
in descending order

87 papers	2,350 citations	201674 27 h-index	254184 43 g-index
88 all docs	88 docs citations	88 times ranked	2144 citing authors

#	Article	IF	Citations
1	Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology, 2017, 88, 143-151.	1.1	135
2	Muscle strength and motor function throughout life in a crossâ€sectional cohort of 180 patients with spinal muscular atrophy types 1câ€“4. European Journal of Neurology, 2018, 25, 512-518.	3.3	126
3	<scp>RYR</scp>1â€related myopathies: a wide spectrum of phenotypes throughout life. European Journal of Neurology, 2015, 22, 1094-1112.	3.3	111
4	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 513-522.	10.2	95
5	Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatology, The, 2022, 4, e338-e350.	3.9	88
6	Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology, 2012, 79, 2050-2055.	1.1	85
7	European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. European Journal of Paediatric Neurology, 2020, 28, 38-43.	1.6	74
8	Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet Journal of Rare Diseases, 2017, 12, 67.	2.7	67
9	Natural history of lung function in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2020, 15, 88.	2.7	56
10	Population-based analysis of survival in spinal muscular atrophy. Neurology, 2020, 94, e1634-e1644.	1.1	54
11	Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cellâ€“derived model. Annals of Neurology, 2016, 80, 71-88.	5.3	53
12	A comparative study of brachial plexus sonography and magnetic resonance imaging in chronic inflammatory demyelinating neuropathy and multifocal motor neuropathy. European Journal of Neurology, 2017, 24, 1307-1313.	3.3	51
13	Galectinâ€9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. Arthritis and Rheumatology, 2019, 71, 1377-1390.	5.6	51
14	Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. Neurology, 2019, 93, e149-e158.	1.1	45
15	Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology, 2020, 95, e1988-e1998.	1.1	44
16	Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. Neurology, 2020, 94, e1470-e1479.	1.1	38
17	Bulbar muscle MRI changes in patients with SMA with reduced mouth opening and dysphagia. Neurology, 2014, 83, 1060-1066.	1.1	37
18	MRI shows thickening and altered diffusion in the median and ulnar nerves in multifocal motor neuropathy. European Radiology, 2017, 27, 2216-2224.	4.5	37

#	Article	IF	Citations
19	Impact of newborn screening for veryâ€longâ€chain acylâ€CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes. Journal of Inherited Metabolic Disease, 2019, 42, 414-423.	3.6	36
20	Correlates of health related quality of life in adult patients with spinal muscular atrophy. Muscle and Nerve, 2016, 54, 850-855.	2.2	35
21	Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency. PLoS ONE, 2016, 11, e0147818.	2.5	35
22	Second intravenous immunoglobulin dose in patients with Guillain-BarrÃ© syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 275-283.	10.2	34
23	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatology, The, 2022, 4, e417-e429.	3.9	33
24	A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls. PLoS ONE, 2016, 11, e0167087.	2.5	32
25	Comparative study of peripheral nerve Mri and ultrasound in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle and Nerve, 2016, 54, 1133-1135.	2.2	32
26	Nerve ultrasound. Neurology, 2019, 92, .	1.1	32
27	Nerve ultrasound for diagnosing chronic inflammatory neuropathy. Neurology, 2020, 95, e1745-e1753.	1.1	32
28	Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy. Brain Communications, 2020, 2, fcaa075.	3.3	32
29	MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability. Brain, 2017, 140, 2093-2103.	7.6	31
30	Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2â€“4 (SPACE trial). BMJ Open, 2018, 8, e019932.	1.9	31
31	Nerve sonography to detect peripheral nerve involvement in vasculitis syndromes. Neurology: Clinical Practice, 2016, 6, 293-303.	1.6	30
32	Nerve ultrasound can identify treatmentâ€responsive chronic neuropathies without electrodiagnostic features of demyelination. Muscle and Nerve, 2019, 60, 415-419.	2.2	29
33	Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests. BMC Neurology, 2019, 19, 21.	1.8	27
34	Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study. Journal of Neuromuscular Diseases, 2020, 7, 323-330.	2.6	27
35	T₂ relaxationâ€time mapping in healthy and diseased skeletal muscle using extended phase graph algorithms. Magnetic Resonance in Medicine, 2020, 84, 2656-2670.	3.0	27
36	Mandibular dysfunction as a reflection of bulbar involvement in SMA type 2 and 3. Neurology, 2016, 86, 552-559.	1.1	26

#	Article	IF	Citations
37	Physical exercise training for type 3 spinal muscular atrophy. The Cochrane Library, 2019, 2019, CD012120.	2.8	26
38	Drug treatment for spinal muscular atrophy types II and III. The Cochrane Library, 2020, 1, CD006282.	2.8	26
39	Nutritional ketosis improves exercise metabolism in patients with very longâ€chain acylâ€CoA dehydrogenase deficiency. Journal of Inherited Metabolic Disease, 2020, 43, 787-799.	3.6	26
40	Association of the FcÎ³ receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients. Journal of Neuroimmunology, 2003, 144, 143-147.	2.3	25
41	Bulbar Problems Self-Reported by Children and Adults with Spinal Muscular Atrophy. Journal of Neuromuscular Diseases, 2019, 6, 361-368.	2.6	23
42	Assessment of motor unit loss in patients with spinal muscular atrophy. Clinical Neurophysiology, 2020, 131, 1280-1286.	1.5	23
43	Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. Orphanet Journal of Rare Diseases, 2020, 15, 75.	2.7	22
44	Correlates of Fatigability in Patients With Spinal Muscular Atrophy. Neurology, 2021, 96, e845-e852.	1.1	20
45	Participation and mental well-being of mothers of home-living patients with spinal muscular atrophy. Neuromuscular Disorders, 2019, 29, 321-329.	0.6	18
46	Metalloprotease-mediated cleavage of PlexinD1 and its sequestration to actin rods in the motoneuron disease spinal muscular atrophy (SMA). Human Molecular Genetics, 2017, 26, 3946-3959.	2.9	17
47	A continuous repetitive task to detect fatigability in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2018, 13, 160.	2.7	17
48	Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk. Rheumatology, 2021, 60, 785-801.	1.9	16
49	Neuropathy associated with immunoglobulin M monoclonal gammopathy: A combined sonographic and nerve conduction study. Muscle and Nerve, 2019, 60, 263-270.	2.2	15
50	Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscular Disorders, 2020, 30, 959-969.	0.6	15
51	Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Medicine, 2022, 20, 100.	5.5	15
52	Clinical outcomes in multifocal motor neuropathy. Neurology, 2020, 95, e1979-e1987.	1.1	13
53	Analysis of FUS, PFN2, TDP-43, and PLS3 as potential disease severity modifiers in spinal muscular atrophy. Neurology: Genetics, 2020, 6, e386.	1.9	13
54	Low interrater reliability of brachial plexus MRI in chronic inflammatory neuropathies. Muscle and Nerve, 2020, 61, 779-783.	2.2	13

#	Article	IF	Citations
55	Effect of mechanical insufflationâ€exsufflation in children with neuromuscular weakness. Pediatric Pulmonology, 2020, 55, 510-513.	2.0	12
56	Magnetic resonance reveals mitochondrial dysfunction and muscle remodelling in spinal muscular atrophy. Brain, 2022, 145, 1422-1435.	7.6	12
57	Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study. Orphanet Journal of Rare Diseases, 2022, 17, 70.	2.7	12
58	The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. Health Policy, 2018, 122, 1287-1294.	3.0	11
59	Drug treatment for spinal muscular atrophy type I. The Cochrane Library, 2019, 12, CD006281.	2.8	11
60	Validation of a Fast, Robust, Inexpensive, Two-Tiered Neonatal Screening Test algorithm on Dried Blood Spots for Spinal Muscular Atrophy. International Journal of Neonatal Screening, 2019, 5, 21.	3.2	10
61	High-resolution ultrasound in patients with Wartenbergâ€™s migrant sensory neuritis, a case-control study. Clinical Neurophysiology, 2018, 129, 232-237.	1.5	9
62	Psychological well-being in adults with spinal muscular atrophy: the contribution of participation and psychological needs. Disability and Rehabilitation, 2020, 42, 2262-2270.	1.8	9
63	Mastication in Patients with Spinal Muscular Atrophy Types 2 and 3 is Characterized by Abnormal Efficiency, Reduced Endurance, and Fatigue. Dysphagia, 2022, 37, 715-723.	1.8	9
64	Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiation. ACS Omega, 2021, 6, 35375-35388.	3.5	9
65	Cytokine profiles in multifocal motor neuropathy and progressive muscular atrophy. Journal of Neuroimmunology, 2015, 286, 1-4.	2.3	8
66	Illness Perceptions in Pediatric Spinal Muscular Atrophy: Agreement between Children and their Parents, and its Association with Quality of Life. Journal of Developmental and Physical Disabilities, 2021, 33, 297-310.	1.6	8
67	Magnetic resonance imaging of the cervical spinal cord in spinal muscular atrophy. NeuroImage: Clinical, 2019, 24, 102002.	2.7	7
68	Parentsâ€™ perspectives on nusinersen treatment for children with spinal muscular atrophy. Developmental Medicine and Child Neurology, 2021, 63, 816-823.	2.1	7
69	Clinical outcome of CIDP oneÂyear after start of treatment: a prospective cohort study. Journal of Neurology, 2022, 269, 945-955.	3.6	7
70	Oscillometry: A substitute of spirometry in children with neuromuscular diseases?. Pediatric Pulmonology, 2022, 57, 1618-1624.	2.0	7
71	Quantitative magnetic resonance imaging of the brachial plexus shows specific changes in nerve architecture in chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and motor neuron disease. European Journal of Neurology, 2021, 28, 2716-2726.	3.3	6
72	Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	5

#	Article	IF	Citations
73	Genetic, biochemical and clinical spectrum of patients with mitochondrial trifunctional protein deficiency identified after introduction of newborn screening in the Netherlands. Journal of Inherited Metabolic Disease, 2022, , .	3.6	5
74	Short-term effect of air stacking and mechanical insufflationâ€“exsufflation on lung function in patients with neuromuscular diseases. Chronic Respiratory Disease, 2022, 19, 147997312210946.	2.4	5
75	Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy. Journal of Neurology, 2019, 266, 2734-2742.	3.6	4
76	Motor unit reserve capacity in spinal muscular atrophy during fatiguing endurance performance. Clinical Neurophysiology, 2021, 132, 800-807.	1.5	4
77	Skeletal muscle training for spinal muscular atrophy type 3. The Cochrane Library, 0, , .	2.8	3
78	Multiâ€parametric quantitative magnetic resonance imaging of the upper arm muscles of patients with spinal muscular atrophy. NMR in Biomedicine, 2022, 35, e4696.	2.8	3
79	Relative hyperventilation in non-ventilated patients with spinal muscular atrophy. European Respiratory Journal, 2020, 56, 2000162.	6.7	2
80	Shortâ€term effect and effect on rate of lung function decline after surgery for neuromuscular or syndromic scoliosis. Pediatric Pulmonology, 2022, 57, 1303-1309.	2.0	2
81	â€˜This battle, between your gut feeling and your mind. Try to find the right balanceâ€™: Parental experiences of children with spinal muscular atrophy during COVIDâ€19 pandemic. Child: Care, Health and Development, 2022, 48, 1062-1070.	1.7	2
82	Electrophysiology of fatigue in chronic inflammatory demyelinating polyneuropathy: Can it be useful?. Clinical Neurophysiology, 2020, 131, 2912-2914.	1.5	1
83	Response to letter: A decision for life â€“ Treatment decisions in newly diagnosed families with spinal muscular atrophy. European Journal of Paediatric Neurology, 2021, 30, 103-104.	1.6	1
84	High-resolution mapping identifies HLA class II associations with multifocal motor neuropathy. Neurobiology of Aging, 2021, 101, 79-84.	3.1	1
85	MRI of the intraspinal nerve roots in patients with chronic inflammatory neuropathies: abnormalities correlate with clinical phenotypes. Journal of Neurology, 2022, , 1.	3.6	1
86	Motor Unit and Capillary Recruitment During Fatiguing Arm-Cycling Exercise in Spinal Muscular Atrophy Types 3 and 4. Journal of Neuromuscular Diseases, 2022, , 1-13.	2.6	1
87	SMN1 Duplications Are Associated With Progressive Muscular Atrophy, but Not With Multifocal Motor Neuropathy and Primary Lateral Sclerosis. Neurology: Genetics, 2021, 7, e598.	1.9	0